title: Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia.
abstract: OBJECTIVE
  We sought to compare the synthesis and metabolism of VLDL1 and VLDL2 in patients with type 2 diabetes mellitus (DM2) and nondiabetic subjects.
  
  
  RESULTS
  We used a novel multicompartmental model to simultaneously determine the kinetics of apolipoprotein (apo) B and triglyceride (TG) in VLDL1 and VLDL2 after a bolus injection of [2H3]leucine and [2H5]glycerol and to follow the catabolism and transfer of the lipoprotein particles. Our results show that the overproduction of VLDL particles in DM2 is explained by enhanced secretion of VLDL1 apoB and TG. Direct production of VLDL2 apoB and TG was not influenced by diabetes per se. The production rates of VLDL1 apoB and TG were closely related, as were the corresponding pool sizes. VLDL1 and VLDL2 compositions did not differ in subjects with DM2 and controls, and the TG to apoB ratio of newly synthesized particles was very similar in the 2 groups. Plasma glucose, insulin, and free fatty acids together explained 55% of the variation in VLDL1 TG production rate.
  
  
  CONCLUSIONS
  Insulin resistance and DM2 are associated with excess hepatic production of VLDL1 particles similar in size and composition to those in nondiabetic subjects. We propose that hyperglycemia is the driving force that aggravates overproduction of VLDL1 in DM2.
authors.affiliation: Department of Mathematical Sciences, Chalmers University of Technology, Göteborg, Sweden.
authors.forename: Martin
authors.initials: M
authors.lastname: Adiels
authors.forename: Jan
authors.initials: J
authors.lastname: Borén
authors.forename: Muriel J
authors.initials: MJ
authors.lastname: Caslake
authors.forename: Philip
authors.initials: P
authors.lastname: Stewart
authors.forename: Aino
authors.initials: A
authors.lastname: Soro
authors.forename: Jukka
authors.initials: J
authors.lastname: Westerbacka
authors.forename: Bernt
authors.initials: B
authors.lastname: Wennberg
authors.forename: Sven-Olof
authors.initials: SO
authors.lastname: Olofsson
authors.forename: Chris
authors.initials: C
authors.lastname: Packard
authors.forename: Marja-Riitta
authors.initials: MR
authors.lastname: Taskinen
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D001786:Blood Glucose; D008076:Cholesterol, HDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000096:biosynthesis* / Q000097:blood*; D003903:Deuterium; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000378:metabolism*; D050171:Dyslipidemias / Q000150:complications / Q000378:metabolism*; D005990:Glycerol / Q000493:pharmacokinetics; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000378:metabolism*; D007333:Insulin Resistance; D007930:Leucine / Q000493:pharmacokinetics; D008297:Male; D014280:Triglycerides / Q000097:blood
chemical_list: D001055:Apolipoproteins B; D001786:Blood Glucose; D008076:Cholesterol, HDL; D015243:Cholesterol, VLDL; D014280:Triglycerides; D003903:Deuterium; D007930:Leucine; D005990:Glycerol